FR2753630A1 - Use of feminine sanitary protection products - Google Patents

Use of feminine sanitary protection products Download PDF

Info

Publication number
FR2753630A1
FR2753630A1 FR9611475A FR9611475A FR2753630A1 FR 2753630 A1 FR2753630 A1 FR 2753630A1 FR 9611475 A FR9611475 A FR 9611475A FR 9611475 A FR9611475 A FR 9611475A FR 2753630 A1 FR2753630 A1 FR 2753630A1
Authority
FR
France
Prior art keywords
periodic
support
protections
protections according
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR9611475A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONTMARIN JEAN LUC DE
Original Assignee
MONTMARIN JEAN LUC DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONTMARIN JEAN LUC DE filed Critical MONTMARIN JEAN LUC DE
Priority to FR9611475A priority Critical patent/FR2753630A1/en
Priority to PCT/FR1998/000556 priority patent/WO1999047121A1/en
Publication of FR2753630A1 publication Critical patent/FR2753630A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/528—Atypical element structures, e.g. gloves, rods, tampons, toilet paper
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Abstract

The use of internal or external feminine sanitary protection, either as a system for application of treatments, of active, preventative or curative agents, or of hygiene products, or as a support for reagents or for taking samples, is new.

Description

UTILISATION DES PROTECTIONS PERIODIQUES FEMININES EXTERNES OU INTERNES
COMME SUPPORT DE TRAITEMENTS PREVENTIFS OU CURATIFS, DE REACTIFS OU
COMME MOYEN DE PRELEVEMENT BIOLOGIQUE
1- DESCRIPTION
DOMAINE TECHNIQUE DE L'INVENTION
La voie vaginale est couramment utilisée pour l'administration de médicaments. Différents supports sont utilisés: ovules, gélules ou gels.USE OF PERIODIC PROTECTION, EXTERNAL OR INTERNAL
AS A SUPPORT FOR PREVENTIVE OR CURATIVE TREATMENTS, REAGENTS OR
AS A BIOLOGICAL SAMPLING MEANS
1- DESCRIPTION
TECHNICAL FIELD OF THE INVENTION
The vaginal route is commonly used for the administration of drugs. Different supports are used: ova, capsules or gels.

Le présent brevet envisage certaines possibilités intéressantes des protections périodiques, jusque là méconnues, dans les domaines du diagnostique médical, de la thérapeutique et des produits d'hygiène.The present patent envisages certain interesting possibilities of periodic protections, hitherto unknown, in the fields of medical diagnostics, therapeutics and hygiene products.

Elles restent en place quelques heures, se positionnent naturellement, sont de manipulation simple et courante par les femmes elles même et peuvent être récupérées.They remain in place for a few hours, are positioned naturally, are simple and common to handle by the women themselves and can be recovered.

Pendant la période menstruelle leur utilisation est naturelle et obligatoire.During the menstrual period their use is natural and compulsory.

Les protections, externes et surtout intra-vaginales représentent un véritable outil galénique, support logique pour des principes actifs, médicamenteux ou autres, pour une flore microbiologique, éventuellement associés à un ou des vecteurs (par exemple céramides). Ce support peut aussi permettre des prélèvements au cours des différentes phases du cycle menstruel ou de la grossesse.The protections, external and especially intravaginal, represent a real galenical tool, logical support for active principles, medicinal or other, for a microbiological flora, possibly associated with one or more vectors (for example ceramides). This support can also allow samples to be taken during the different phases of the menstrual cycle or pregnancy.

La protection, qu'elie soit externe ou intra-vaginale, peut être:
le support des principes actifs par sa texture, le produit étant fixé directement à la protection par
des liaisons chimiques, des forces électrostatiques, ou par l'intermédiaire d'une capsule ou de
micro-capsules contenant le ou les principes actifs;
elle même, le ou un des principes actifs de par sa composition chimique;
un outil de prélèvements biologiques, microbiologiques, cytologiques etlou de transport par sa
structure physique;
un support de principes actifs et un outil de prélèvement en même temps.Protection, whether external or intravaginal, can be:
the support of the active ingredients by its texture, the product being directly attached to the protection by
chemical bonds, electrostatic forces, or through a capsule or
microcapsules containing the active ingredient (s);
itself, the or one of the active ingredients by its chemical composition;
a biological, microbiological, cytological and / or transport tool for its
physical structure;
support for active ingredients and a sampling tool at the same time.

De nombreuses pathologies féminines sont rythmées par les cycles et s'expriment justement lors de la phase menstruelle. II paraît logique d'utiliser la coexistence naturelle du support et de la pathologie.Many female pathologies are punctuated by cycles and are expressed precisely during the menstrual phase. It seems logical to use the natural coexistence of the support and the pathology.

Les protections périodiques peuvent donc faire l'objet de plusieurs types d'applications dans divers domaines en rapport avec la physiologie ou les pathologies féminines:
Prévention: reposant sur la périodicité menstruelle, le support permet l'application d'agents
physiques, chimiques ou micro-organismes (levures ou bacilles);
Thérapeutique: au moment d'une symptomatologie physiologique ou pathologique;
Dépistage: supports de prélèvement pour frottis, glaires cervicales,support de réactifs
(pH, dépistage microbiologique);
Contraception / fertilité: dépistage etlou modification etlou destruction de la glaire cervicale;
Obstétrique: prévention etlou traitement des contractions pathologiques;
dépistage de rupture des membranes,
réalité d'une menace d'accouchement prématuré,
déclenchement d'accouchement; Contention mécanique pour prévenir ou traiter l'incontinence urinaire
ETAT DE LA TECHNIQUE ANTERIEURE
La voie vaginale est utilisée depuis longtemps pour administrer des traitements, médicaments en particulier, sous forme de comprimés, d'ovules, de crèmes. Nous n'avons jamais vu apparaitre l'idée d'utiliser les protections périodiques comme support de traitement ou de diagnostique dans les publications médicales destinées aux spécialistes en gynécologie-obstétnque. Periodic protection can therefore be the subject of several types of applications in various fields related to physiology or female pathologies:
Prevention: based on menstrual periodicity, the support allows the application of agents
physical, chemical or micro-organisms (yeasts or bacilli);
Therapeutic: at the time of a physiological or pathological symptomatology;
Screening: swab specimen holders, cervical mucus, reagent holder
(pH, microbiological screening);
Contraception / fertility: screening and / or modification and / or destruction of cervical mucus;
Obstetrics: prevention and / or treatment of pathological contractions;
membrane rupture screening,
reality of a threat of premature birth,
induction of childbirth; Mechanical restraint to prevent or treat urinary incontinence
STATE OF THE PRIOR ART
The vaginal route has been used for a long time to administer treatments, drugs in particular, in the form of tablets, ova, creams. We have never seen the idea of using periodic protections appear as a treatment or diagnostic support in medical publications intended for specialists in gynecology-obstetrics.

Cependant l'intérêt d'un tel procédé ne fait aucun doute par l'efficacité et le confort qu'il apporte.However the interest of such a process is beyond doubt by the efficiency and the comfort which it brings.

Les comprimés et les ovules ont de nombreux inconvénients d'utilisation par rapport aux protections périodiques. Leur mise en place est contraignante et souvent pas optimale pour une bonne biodisponibilité du principe actif. Pendant la période des règles on ne peut tirer un quelconque avantage de cette spécificité physiologique. De toutes façons, I'effet de coulage, pratiquement constant pour les ovules ou les comprimés, impose généralement l'utilisation de protections.Tablets and eggs have many disadvantages of use compared to periodic protections. Their implementation is restrictive and often not optimal for good bioavailability of the active ingredient. During the period of menstruation one cannot derive any advantage from this physiological specificity. In any case, the pouring effect, practically constant for the ova or the tablets, generally requires the use of protections.

Enfin, seules les protections périodiques permettent les prélèvements ou leur transport. Finally, only periodic protections allow direct debits or their transport.

Claims (6)

2- REVENDICATIONS 2- CLAIMS 1) Revendication principale: utilisation des protections périodiques féminines, externes et surtout intra-vaginales, soit comme système d'application de traitements, de principes actifs, préventifs et curatifs, ou de produits d'hygiène, soit comme support de prélèvement ou de réactif.1) Main claim: use of periodic feminine protections, external and especially intravaginal, either as a system for applying treatments, active, preventive and curative principles, or hygiene products, or as a sample or reagent support . Soit préventif pendant la phase menstruelle. Either preventive during the menstrual phase. Revendications dépendantes: 2) Utilisation des protections périodiques selon la revendication 1 comme un support de principe actif permettant l'application de traitements. Le traitement peut être:Dependent claims: 2) Use of the periodic protections according to claim 1 as a support for active principle allowing the application of treatments. The treatment can be: Soit thérapeutique au moment où la symptomatologie est présente. Either therapeutic when the symptomatology is present. détruire la glaire cervicale. destroy cervical mucus. . Soit dans les domaines de la contraception et de la fertilité humaine pour évaluer, modifier ou . Either in the fields of contraception and human fertility to assess, modify or - en fin de grossesse, menace ou/et déclenchement de l'accouchement. - at the end of pregnancy, threat or / and initiation of childbirth. - en cours de grossesse, prévention ou traitement des contractions pathologiques; - during pregnancy, prevention or treatment of pathological contractions; Soit en obstétrique: Either in obstetrics: 3) Utilisation des protections périodiques selon la revendication 1 en tant que support d'une flore micro-biologique lyophilisée de réensemencement ou de rééquilibrage vaginal.3) Use of the periodic protections according to claim 1 as a support for a freeze-dried micro-biological flora for reseeding or vaginal rebalancing. de dépistage microbiologique; sensibles à l'état physiologique ou biochimique du tractus génital. microbiological screening; sensitive to the physiological or biochemical state of the genital tract. 4) Utilisation des protections périodiques selon la revendication 1 en tant que support de réactifs:4) Use of the periodic protections according to claim 1 as a support for reagents: 5) Utilisation des protections périodiques selon la revendication 1 en tant que support de prélèvements biologiques ou cytologiques vaginaux.5) Use of the periodic protections according to claim 1 as a support for vaginal biological or cytological samples. 6) Utilisation des protections périodiques selon la revendication 1 en tant que support de contention mécanique pour prévenir ou traiter une incontinence urinaire. 6) Use of the periodic protections according to claim 1 as a mechanical support for preventing or treating urinary incontinence.
FR9611475A 1996-09-20 1996-09-20 Use of feminine sanitary protection products Pending FR2753630A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9611475A FR2753630A1 (en) 1996-09-20 1996-09-20 Use of feminine sanitary protection products
PCT/FR1998/000556 WO1999047121A1 (en) 1996-09-20 1998-03-18 Use of external or internal feminine absorbent articles as support for therapeutic or diagnostic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9611475A FR2753630A1 (en) 1996-09-20 1996-09-20 Use of feminine sanitary protection products
PCT/FR1998/000556 WO1999047121A1 (en) 1996-09-20 1998-03-18 Use of external or internal feminine absorbent articles as support for therapeutic or diagnostic agents

Publications (1)

Publication Number Publication Date
FR2753630A1 true FR2753630A1 (en) 1998-03-27

Family

ID=26232987

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9611475A Pending FR2753630A1 (en) 1996-09-20 1996-09-20 Use of feminine sanitary protection products

Country Status (2)

Country Link
FR (1) FR2753630A1 (en)
WO (1) WO1999047121A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047121A1 (en) * 1996-09-20 1999-09-23 Montmarin Jean Luc De Use of external or internal feminine absorbent articles as support for therapeutic or diagnostic agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102152L (en) * 2001-06-18 2002-12-19 Sca Hygiene Prod Ab New product
WO2006042871A1 (en) * 2004-09-14 2006-04-27 Sator & Fata, S.L. Compress for female use
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7919453B2 (en) 2005-03-25 2011-04-05 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US7744556B2 (en) 2005-03-25 2010-06-29 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US7708726B2 (en) 2005-04-28 2010-05-04 Kimberly-Clark Worldwide, Inc. Dosage form cap for an applicator
BR112016026510A2 (en) 2014-05-15 2017-08-15 Gruenenthal Gmbh DEVICE AND FORMULATION FOR TOPICAL TREATMENT OF PAIN AFFECTING THE VULVAR AREA OF THE FEMALE GENITAL ORGANIC

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850160A (en) * 1973-02-15 1974-11-26 J Denson Diagnostic tampon and the use thereof for collecting cellular material
US3902493A (en) * 1974-05-13 1975-09-02 Procter & Gamble Medicated catamenial tampon
US3934575A (en) * 1973-02-05 1976-01-27 Louis Bucalo Tampon device to test for micro-organisms
WO1987004069A1 (en) * 1986-01-11 1987-07-16 Joseph Jacob Antitoxin vaginal products and catamenials comprising ascorbic acid
US4724204A (en) * 1982-08-23 1988-02-09 Medi-Pharma Vertriebsgesellschaft Mbh Diagnostic device for the detection of increased dehydrogenase or oxidase and the use thereof
US5045079A (en) * 1987-06-15 1991-09-03 Prosthex Limited Method for alleviating female urinary incontinence
WO1992013577A1 (en) * 1991-02-05 1992-08-20 Lecur Development In Sweden Aktiebolag Tampon or sanitary napkin provided with lactic acid producing bacteria
US5156164A (en) * 1988-10-13 1992-10-20 Leveen Harry H Iodine contraceptive sponge
JPH05123324A (en) * 1991-11-05 1993-05-21 Hakujiyuuji Kk Pad for judging amniorrhexis of amniotic fluid
WO1994008536A1 (en) * 1992-10-21 1994-04-28 Gynetech Laboratories, Inc. Vaginal sponge delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753630A1 (en) * 1996-09-20 1998-03-27 Montmarin Jean Luc De Use of feminine sanitary protection products

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934575A (en) * 1973-02-05 1976-01-27 Louis Bucalo Tampon device to test for micro-organisms
US3850160A (en) * 1973-02-15 1974-11-26 J Denson Diagnostic tampon and the use thereof for collecting cellular material
US3902493A (en) * 1974-05-13 1975-09-02 Procter & Gamble Medicated catamenial tampon
US4724204A (en) * 1982-08-23 1988-02-09 Medi-Pharma Vertriebsgesellschaft Mbh Diagnostic device for the detection of increased dehydrogenase or oxidase and the use thereof
WO1987004069A1 (en) * 1986-01-11 1987-07-16 Joseph Jacob Antitoxin vaginal products and catamenials comprising ascorbic acid
US5045079A (en) * 1987-06-15 1991-09-03 Prosthex Limited Method for alleviating female urinary incontinence
US5156164A (en) * 1988-10-13 1992-10-20 Leveen Harry H Iodine contraceptive sponge
WO1992013577A1 (en) * 1991-02-05 1992-08-20 Lecur Development In Sweden Aktiebolag Tampon or sanitary napkin provided with lactic acid producing bacteria
JPH05123324A (en) * 1991-11-05 1993-05-21 Hakujiyuuji Kk Pad for judging amniorrhexis of amniotic fluid
WO1994008536A1 (en) * 1992-10-21 1994-04-28 Gynetech Laboratories, Inc. Vaginal sponge delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 017, no. 482 (C - 1105) 2 September 1993 (1993-09-02) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047121A1 (en) * 1996-09-20 1999-09-23 Montmarin Jean Luc De Use of external or internal feminine absorbent articles as support for therapeutic or diagnostic agents

Also Published As

Publication number Publication date
WO1999047121A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
Alderete et al. Pathogenic Trichomonas vaginalis cytotoxicity to cell culture monolayers.
Fox et al. Detection of HIV-1 RNA in the lamina propria of patients with AIDS and gastrointestinal disease
Holden et al. Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes
TNSN00036A1 (en) NOVEL OXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2753630A1 (en) Use of feminine sanitary protection products
TNSN00028A1 (en) NEW HETEROARYL SUBSTITUTE QUINOLEIN -2-ONE DERIVATIVES NEW PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
TNSN99253A1 (en) CHEMICAL COMPOUNDS NOVEL MODULATORS OF CCR5, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
TNSN98019A1 (en) ARYLSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
UA49803C2 (en) Method for treatment of retrovirus infections
Yamamoto et al. New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single-blind study
JPH09506428A (en) Detection and treatment of breast and gynecological cancers
JPH01502194A (en) Molecules comprising at least one peptide sequence having one or more characteristic epitopes of a protein produced by Plasmodium vivax in hepatocytes, and compounds comprising these molecules
Wulff et al. Clinical pharmacological aspects of valproate sodium
RU2003118583A (en) REPINOTANE KIT
FR2611274A1 (en) AIDS DETECTION ASSEMBLY, METHOD FOR DETERMINING AIDS RISKS AND THERAPEUTIC COMPOSITION AGAINST THE SAME
Bravo et al. Cutaneous manifestations of infection by free-living amebas
Lapins et al. Skin and mucosal characteristics of symptomatic primary HIV-1 infection
TNSN99159A1 (en) POLYMORPHIC FORM OF ZOPOLRESTAT MONOHYDRATE, METHODS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE60225587T2 (en) PROTEASE ASSAY TO CONTROL MEDICINAL THERAPY
Mulanga-Kabeya et al. Prevalence and risk assessment for sexually transmitted infections in pregnant women and female sex workers in Mali: is syndromic approach suitable for screening?
Prevot et al. Detection by in situ hybridization of HIV I RNA in spleens of HIV I sero-positive patients with thrombocytopenic purpura
Chaudhuri et al. A double-blind controlled clinical trial of carnidazole and tinidazole in the treatment of vaginal trichomoniasis
Takahashi et al. Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide
Kaplan The AIDS epidemic and the drug substance abuse patient
SU1506355A1 (en) Method of diagnosis of aggravation of chronic recurring pancreatitis